| 0 (0%) | 09-27 14:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.51 |
1-year : | 6.06 |
| Resists | First : | 4.71 |
Second : | 5.19 |
| Pivot price | 4.76 |
|||
| Supports | First : | 3.94 |
Second : | 3.28 |
| MAs | MA(5) : | 4.63 |
MA(20) : | 4.82 |
| MA(100) : | 4.14 |
MA(250) : | 3.93  |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 40 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 6.71 | Low : | 2.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORGO ] has closed below the lower bollinger band by 26.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ORGO ] is to continue within current trading range. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.68 - 4.71 | 4.71 - 4.73 |
| Low: | 3.89 - 3.92 | 3.92 - 3.94 |
| Close: | 4.06 - 4.1 | 4.1 - 4.14 |
Fri, 26 Sep 2025
$ORGO stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
Fri, 26 Sep 2025
Organogenesis (NASDAQ:ORGO) Shares Down 11.3% - What's Next? - MarketBeat
Fri, 26 Sep 2025
Organogenesis (NASDAQ:ORGO) Given "Buy" Rating at BTIG Research - MarketBeat
Fri, 26 Sep 2025
New Analyst Forecast: $ORGO Given $7.0 Price Target - Quiver Quantitative
Thu, 25 Sep 2025
Organogenesis hits setback as second late-stage ReNu study misses key endpoint (ORGO:NASDAQ) - Seeking Alpha
Thu, 25 Sep 2025
6.9-Point Pain Reduction: Organogenesis ReNu Shows Promise in Knee Osteoarthritis Despite Missing P-Value - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 127 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 46.6 (%) |
| Held by Institutions | 54.9 (%) |
| Shares Short | 10,190 (K) |
| Shares Short P.Month | 9,780 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.84 |
| Profit Margin | -2 % |
| Operating Margin | -10.8 % |
| Return on Assets (ttm) | -2.1 % |
| Return on Equity (ttm) | -2.7 % |
| Qtrly Rev. Growth | -22.4 % |
| Gross Profit (p.s.) | 2.52 |
| Sales Per Share | 3.38 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -29.29 |
| PEG Ratio | 0 |
| Price to Book value | 2.22 |
| Price to Sales | 1.21 |
| Price to Cash Flow | -15.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|